Shire Receives Approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan
Shire Announces FDA Approval of TAKHZYRO (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
New Drug Application Submitted in Japan for INTUNIV (guanfacine hydrochloride extended release) in Adults with ADHD
Blue Lagoon Secures $2 Million Line of Credit from Nicola Mining Enhancing Financial Flexibility Ahead of Production
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements
